Cardiac Insight

Cardiac Insight was co-founded by Dr. Dave Hadley and Dr. Vic Froelicher. Hadley, a Caltech Ph.D., previously co-founded Sierra Geophysics and focuses on algorithm development and product innovation. Froelicher is a cardiologist who contributed to the Stanford Criteria for ECG interpretation, shaping the clinical framework behind the Cardea 20/20 system (per the firm, 2023).

Cardiac Insight's two FDA-cleared products are the Cardea SOLO (cleared 2017) and Cardea 20/20. Cardea SOLO is a 7-day wearable ambulatory ECG sensor with software-assisted analysis for detecting arrhythmias. Cardea 20/20 is a handheld 12-lead ECG system designed to identify hidden cardiac conditions in athletes, using the International Consensus Criteria and achieving a low false-positive rate of ~2% (per the firm, 2023).

Cardiac Insight sells directly to healthcare providers, who can perform analysis in-office using the company's software. The physician retains ownership of patient data. Competitors such as iRhythm typically require sending recorded ECG data to a diagnostic service provider (DSP) for interpretation, which can increase turnaround time and data handling complexity (per the firm, 2023).

Cardiac Insight is a privately held medical device company with an approved, commercialized product generating revenue. It is beyond the seed or Series A stage, with a strategic partnership with DreamTech established in 2021. The firm's capital requirements are likely focused on scaling manufacturing, regulatory expansion, and commercial growth rather than R&D-stage risk.

Cardiac Insight is an operating medical device company, not a family office. It develops, manufactures, and sells ECG diagnostic products. No information indicates it invests in third-party funds or manages outside capital.

Cardiac Insight is headquartered in Bellevue, Washington, United States. The firm's website and clinical references are in English; it does not publicly disclose international regulatory clearances beyond the US FDA. Competitor comparisons mention multiple US-based device manufacturers, suggesting a primary focus on the North American market.